News Release

Research Article Cites HemogloBind™ in Malaria Study of Reticulocytes

MONMOUTH JUNCTION, NJ, July 31, 2018 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for improving Western blot analysis from reticulocytes. The citation is:

Junqueira, Caroline, et al. "Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax–infected reticulocytes." Nature medicine (2018): 1.

The Malaria parasite Plasmodium vivax causes approximately 100 million clinical cases yearly. The basis of protective immunity is poorly understood yet thought to be mediated by antibodies. The authors hypothesized that CD8⁺ T Cells in patient with P. vivax malaria might become activated by recognizing P. vivax-infected reticulocytes (iRetics), causing them to degranulate. To evaluate the expression levels of proteins involved in antigen presentation in reticulocytes by Western blot, the article states “Cell lysates of reticulocytes…were analyzed by immunoblot…after hemoglobin removal using HemogloBind™ (Biotech Support Group)”. The authors conclude that P. vivax renders reticulocytes granulysin-susceptible and that this unexpected T Cell defense might be mobilized to improve vaccines.

“The large amount of hemoglobin in whole blood presents a special challenge for quantitative Western blot analysis. Here is another article demonstrating that HemogloBind™ can reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the protein of interest.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.  

For more information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com